Abstract 14035: Clinical Outcomes Following Hospitalization for COVID-19 in Patients With Cardiac Sarcoidosis in the United States

Abstract

Background: Chronic immunosuppressive therapy and concomitant pulmonary involvement are two possible factors that could contribute towards adverse outcomes for patients with a history of Cardiac Sarcoidosis (CS) who are hospitalised with Covid-19. In this study, we aimed to identify co-morbidities and clinical outcomes for patients with CS post hospitalization for Covid-19. Methods: Patients aged ≥18 years, with a positive diagnosis of COVID-19 (via ICD-10 code “U071”) between 1st April 2020 to 31st December 2020, were identified from National Inpatient Sample Database. Patients with CS were compared for patient characteristics, demographics and hospital-related outcomes against patients without CS using multivariable regression analysis. Results: We identified a total of 1,608,285 cases of COVID-19 infection admitted to the hospital out of whom 60 patients were confirmed to have CS. CS patients were younger (mean 57.8 vs. 63.3 years, p<0.01), had a higher mean Charlson comorbidity index (CCI: 5.17 vs. 2.72, p<0.01) with greater prevalence of previous myocardial infarction (25.0% vs. 4.2%, p<0.01), atrial fibrillation (58.3% vs. 15.6%, p<0.01), smoking (50% vs. 26.1%, p<0.01), chronic kidney disease (66.7% vs. 20.6%, p<0.01) and diabetes (75.0% vs. 40.0%, p<0.01) as compared to patients without CS. Moreover, clinical outcomes of patients with CS were more adverse following hospitalization for COVID-19 including use of mechanical ventilation (25.0% vs. 11.2%, p<0.01, adjusted OR 1.39 95% CI: 1.37-1.41), acute kidney injury (50.0% vs. 28.2%, p<0.01, adjusted OR 1.86, 95% CI: 1.84-1.88) and death (25.0% vs. 13.1%, p<0.01, adjusted OR 3.15, 95% CI: 3.10- 3.20) (Table 1). Conclusion: CS patients hospitalized for COVID- 19 infection had greater CCI and worse clinical outcomes such as mechanical ventilation use, acute kidney injury and death when compared to patients without cardiac sarcoidosis. Keywords: Cardiac sarcoidosis, COVID- 19, outcomes.